Journal
PHARMACEUTICALS
Volume 16, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/ph16040616
Keywords
proteostasis inhibition; proteostasis disruption; protein unfolding; protein aggregation; IHSF; celastrol; withaferin A; multiple myeloma 1
Categories
Ask authors/readers for more resources
Exposure to celastrol, withaferin A, and synthetic compounds caused denaturation of luciferase reporter protein in cancer cells, leading to proteostasis disruption. Proteomic analysis revealed covalent modification of numerous cellular proteins targeted by the compounds. Important fractions of these proteins unfolded and formed aggregates. Multiple myeloma cells were particularly sensitive to these compounds. Development of a new proteostasis-disrupting therapy for multiple myeloma is suggested.
Exposure of many cancer cells, including multiple myeloma cells, to cytotoxic concentrations of natural products celastrol and withaferin A or synthetic compounds of the IHSF series resulted in denaturation of a luciferase reporter protein. Proteomic analysis of detergent-insoluble extract fractions from HeLa-derived cells revealed that withaferin A, IHSF058 and IHSF115 caused denaturation of 915, 722 and 991 of 5132 detected cellular proteins, respectively, of which 440 were targeted by all three compounds. Western blots showed that important fractions of these proteins, in some cases approaching half of total protein amounts, unfolded. Relatively indiscriminate covalent modification of target proteins was observed; 1178 different proteins were modified by IHSF058. Further illustrating the depth of the induced proteostasis crisis, only 13% of these proteins detectably aggregated, and 79% of the proteins that aggregated were not targets of covalent modification. Numerous proteostasis network components were modified and/or found in aggregates. Proteostasis disruption caused by the study compounds may be more profound than that mediated by proteasome inhibitors. The compounds act by a different mechanism that may be less susceptible to resistance development. Multiple myeloma cells were particularly sensitive to the compounds. Development of an additional proteostasis-disrupting therapy of multiple myeloma is suggested.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available